Wilson Wolf Corporation Valuation, Funding & Investors

Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.

Sansure Biotech Inc is engaged in production and sales of diagnostic reagents and instruments. The company produces Class I medical devices, Class II medical devices, Class III medical devices, general instruments and meters, medical raw materials, medical laboratory equipment and appliances, and medical accessories.

SEEGENE Inc is engaged in the healthcare sector. The Korean firm specializes in developing upgraded technology for accurate diagnosis of various diseases. Its products include pathogen inspection solutions such as respiratory, gastrointestinal, tuberculosis and meningitis pathogens.

Equashield is a medical device manufacturer specializing in closed system transfer devices that prevent exposure to hazardous drugs during compounding and administration. Its flagship product, the Equashield PRO platform, features a needle-free, mechanically closed system compliant with USP <800> standards for handling antineoplastic agents. Headquartered in Port Washington, New York, with operations originating from Israel since its founding in 2007, the company supplies over 1,000 hospitals across North America, Europe, and Asia. Equashield holds FDA 510(k) clearance and NIOSH certification, and it partners with major distributors like McKesson and Cardinal Health to protect pharmacists and nurses from aerosols and vapors.

Everlywell is an Austin, Texas-based digital health company, founded in 2015, that sells at-home lab testing kits for conditions including cholesterol, thyroid health, fertility, testosterone, food sensitivities, and sexually transmitted infections, with results reviewed by physicians through partnered labs. The company added COVID-19 sample collection kits in March 2020, scaling to handle up to 250,000 tests per week during the pandemic. Its direct-to-consumer model combines e-commerce sales of test kits with lab fees, physician review, and subscription revenue for repeat testing.

Lila Sciences is a Boston-based AI platform accelerating discoveries in life sciences, chemistry, and materials. Its tools automate hypothesis generation, experiment design, and data analysis using large language models trained on 100 million publications. Deployed by 50 labs at universities like MIT, it integrates robotic labs for high-throughput synthesis.

Arcs Co Ltd is a Japan-based company principally engaged in the supermarket business. The company also operates other businesses through subsidiaries, including tourism, building maintenance, real estate leasing, property and casualty insurance and life insurance agency, wholesale, food manufacturing, industrial and general waste collection, and construction businesses. The supermarket segment offers a broad range of merchandise, including foods, apparel, and housing-related products.

Shandong Weigao Orthopaedic Device Co Ltd is engaged in the research and development, production and sales of orthopedic medical devices.

Rapid Medical is an Israeli medical technology company that develops minimally invasive devices for the treatment and prevention of stroke. Its products include the Tigertriever revascularization device and the Comaneci adjustable remodeling mesh, both used in neurovascular procedures. Rapid Medical has partnered with MicroPort, which holds exclusive commercial rights to three of the company's flagship products in Greater China.

FibroGen is a biopharmaceutical company discovering therapies based on hypoxia-inducible factor and connective tissue growth factor biology for anemia, fibrosis, and cancer. Its flagship product roxadustat, a HIF-PH inhibitor, received approval in China in 2018 and Japan in 2019 for anemia in chronic kidney disease, with ongoing global trials. Headquartered in San Francisco, California, FibroGen partners with AstraZeneca and Astellas for commercialization in multiple regions.

Aragen Life Sciences is a Hyderabad-based discovery and development organization providing integrated drug discovery, clinical development, and contract manufacturing services across small molecules and biologics for global pharma clients. Formerly GVK Biosciences, it employs 2,400 scientists in facilities totaling 1.2 million square feet in India and the United States. Founded in 2001, Aragen serves top pharmaceutical firms with capabilities in medicinal chemistry, ADME, and GMP manufacturing.

Sangon Biotech is a Shanghai-based biotechnology firm specializing in nucleic acid synthesis and molecular biology products. Founded in 2003 as a Sino-foreign joint venture, it manufactures DNA/RNA oligonucleotides, gene synthesis services, peptides, enzymes, reagents, lab consumables, and benchtop instruments. The company operates a production base in Songjiang Industrial Park, serving research institutions and pharmaceutical companies worldwide.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation’s limited range. The company derives maximum revenue from Israel.

Bonesupport Holding AB is a fast-growing ortho-biologics company that focuses on the treatment of bone disorders. The Company develops and sells injectable bio-ceramic bone graft substitutes based on its CERAMENT platform, which remodels to bone and can release pharmaceuticals to promote healing. Its products focus on trauma, revision arthroplasty (replacement of joint prostheses), chronic osteomyelitis (bone infection), and foot and ankle surgery. The Group manages and monitors operations in two operating segments: North America (NA) and Europe & Rest of the World (EUROW).

MindMaze is a Lausanne-headquartered digital neurotherapeutics company founded in 2012 with offices in Zürich, Ecublens, Switzerland, and San Francisco. It develops medical-grade virtual reality platforms like MindMotionPRO for neurological rehabilitation, offering personalized VR exercises that enhance motor recovery for stroke and brain injury patients. The technology incorporates 3D motion capture, gesture recognition, augmented reality, brain imaging, and neuroscience for intuitive human-machine interfaces. MindMaze's solutions optimize clinician workflows, support therapy dosing, and extend to gaming and brain-computer control applications.

Science is a clinical-stage medical technology company developing brain-computer interfaces for vision restoration, cognitive enhancement, and motor control. San Francisco-headquartered, it offers Axon neural probes, SciFi headstages, and Synapse protocols alongside implantable devices like PRIMA photovoltaic arrays for retinal diseases. The platform integrates neural recording, optogenetics, and software for modular neuroengineering applications.

Huihe Healthcare is a Shanghai-headquartered medical device company established in 2019. The firm specializes in innovative devices addressing structural heart diseases, including transcatheter solutions for mitral and tricuspid valve repair.

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.